Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Fundamentals
Mkt Cap
$215.4M
Volume
-
52W High
$45.00
52W Low
$8.21
PE Ratio
-0.74
Avg. Volume
137,861.96
EPS (Annual)
-$16.06
P/B
0.87
Rev/Employee
$223.60
Earnings
Nov 06
50
Neutral Sentiment
How do you feel about LYEL?
svb64
$LYEL buying more in the 10.70s, replacing shares sold earlier this year. Building up position into end of year
2
terra987
$LYEL The Chinese ICT (LYL273, purchased from there), which holds 3 million shares, apparently sold only a small number of shares for tax reasons. No further selling pressure was observed from that source. So, what’s going on here? Is it all just manipulation? Algorithms? I still believe Lyel will be the next $ABCL ...